Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Bayer

Status: Completed

Conditions: Venous Thromboembolism

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT02558465

17522

XAR-PE-DVT (Other Identifier)

Details and patient eligibility

About

The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This study is a company sponsored, one- arm prospective cohort study with patients to whom Rivaroxaban treatment for VTE (PE/DVT) has been chosen. The study includes a standard observation period (1 year) and an extension survey period (2 years, at the longest).

Enrollment: 2,540 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who start rivaroxaban for VTE(pulmonary embolism, deep vein thrombosis) anticoagulation therapy.

Exclusion criteria

• Patients who are contraindicated based on the product label and have already received Xarelto treatment.

Trial design

2,540 participants in 1 patient group

Rivaroxaban (Xarelto, BAY59-7939)

Description:

Rivaroxavban administration group

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)